Protagenic Therapeutics, Inc.\new
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 149 FIFTH AVENUE, NEW YORK, NY, 10010
Mailing Address 149 FIFTH AVENUE, NEW YORK, NY, 10010
Phone (212) 994-8200
Fiscal Year End 0331
EIN 061390025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | January 5, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | December 5, 2025 | View on SEC |
| 8-K Current report of material events | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 26, 2025 | View on SEC |
| 8-K Current report of material events | November 5, 2025 | View on SEC |
| 8-K Current report of material events | October 31, 2025 | View on SEC |
| 424B5 Prospectus supplement | October 24, 2025 | View on SEC |
| 3 Initial insider ownership report | October 24, 2025 | View on SEC |
| 8-K/A Current report amendment | September 17, 2025 | View on SEC |
| 8-K/A Current report amendment | August 28, 2025 | View on SEC |
Material Events
8-K Financial Distress January 5, 2026
High Impact
- Protagenic Therapeutics' stock and warrants are being delisted from the Nasdaq stock exchange.
- The securities will now trade on the over-the-counter (OTC) market, a less formal market with typically less trading activity.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.